Evidence map›Paper›PMID 32681423›Full record

ArticleClinical oral investigations2021

FAK, paxillin, and PI3K in ameloblastoma and adenomatoid odontogenic tumor.

Ibrahim O Bello, Marwah A Alrabeeah, Naflaa F AlFouzan, Nora A Alabdulaali, Pentti Nieminen

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical oral investigations, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Ibrahim O BelloDepartment of Oral Medicine and Diagnostic Sciences, College of Dentistry, King Saud University, Riyadh, 11545, Saudi Arabia. ibello@ksu.edu.sa.ORCID http://orcid.org/0000-0003-2085-3185
Marwah A AlrabeeahCollege of Dentistry, King Saud University, Riyadh, Saudi Arabia.
Naflaa F AlFouzanCollege of Dentistry, King Saud University, Riyadh, Saudi Arabia.
Nora A AlabdulaaliCollege of Dentistry, King Saud University, Riyadh, Saudi Arabia.
Pentti NieminenMedical Informatics and Statistics Research Group, University of Oulu, Oulu, Finland.
King Saud University · SAUniversity of Helsinki · FIUniversity of Oulu · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveIntegrins function to bind cells to extracellular matrix in tissues, which triggers downstream signaling cascades that are important in cell survival, proliferation, cytokine activation, and cytoskeleton reorganization. These processes also play significant roles in neoplasms. This work aimed to investigate the pattern of expression of FAK, paxillin, and PI3K in ameloblastoma and adenomatoid odontogenic tumor (AOT). MATERIALS AND

methodsImmunohistochemistry was used to study FAK, paxillin, and PI3K in 45 ameloblastomas (32 conventional, 12 unicystic, and 1 peripheral types), 7 AOTs, and two developing human teeth.

resultsWeak expression of FAK was seen in all AOT cases, while ameloblastoma had varying expression patterns, mostly strong to weak. The pattern of expression of paxillin and PI3K was relatively similar in both tumor types. In the dental germ, FAK and paxillin stained all the enamel organ components, while PI3K stained strongly the inner enamel epithelium. Stromal expression of FAK was not found to be useful in differentiating between tumors or tumor classes.

conclusionThe expression of the proteins in the enamel organ suggests that their signaling may be important in odontogenesis. While some ameloblastomas strongly expressed FAK, all cases of AOT had weak signals suggesting low presence and phosphorylating activity of FAK in the latter. CLINICAL RELEVANCE: A subset of FAK-positive ameloblastoma (as well as their malignant or metastasizing counterparts) which may have relatively aggressive behavior may be candidates for drug targeting of FAK as an additional management option.

Indexed as

AmeloblastomaOdontogenic TumorsFocal Adhesion Kinase 1HumansPaxillinPhosphatidylinositol 3-KinasesFocal Adhesion Kinase 1PaxillinPhosphatidylinositol 3-KinasesPTK2 protein, humanAdenomatoid odontogenic tumorAmeloblastomaFAKFocal adhesion kinasePaxillinPI3K

Identifiers

PMID32681423
OpenAlexW3043674705

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.